评估COOMBS阴性非细胞溶血性贫血的个体
Evaluation of individuals with exercise intolerance or myopathy
磷酸果酶缺乏症家族的遗传研究
动力学分光光度法
红细胞磷酸果糖激酶
PFK
磷酸果糖激酶
RBC PFK
全血ACD-B
收集容器/管:
Preferred:Yellow top (ACD solution B)
可接受:薰衣草顶(EDTA)
标本卷:6毫升
Collection Instructions:以原始管子发送标本。不要transfer blood to other containers.
如果不以电子方式订购,请完成,打印并发送良性血液学测试请求(T755)带有标本。
1毫升
Gross hemolysis | Reject |
标本类型 | 温度 | 时间 | Special Container |
---|---|---|---|
全血ACD-B | 冷藏(首选) | 11天 |
评估COOMBS阴性非细胞溶血性贫血的个体
Evaluation of individuals with exercise intolerance or myopathy
磷酸果酶缺乏症家族的遗传研究
磷酸果糖激酶(PFK)是糖酵解中的第三种酶。它将6-磷酸果糖转化为1,6-二磷酸果糖。PFK缺乏症,也称为糖原储存疾病,VII型或塔鲁伊疾病(OMIM 232800),是一种罕见的遗传性常染色体隐性遗传疾病,通常在童年时期注意到。已经描述了不同的临床亚型(经典,晚期,婴儿和溶血性)。表现可能会有所不同,包括运动不耐受,劳累肌病,恶心,僵硬和肌红蛋白尿。尽管没有经典描述,但某些患者注意到了第二风效应(1)。一部分个体具有补偿(正常血红蛋白值)或轻度溶血性贫血,发作性黄疸,高尿酸血症或类似痛风的症状。在外周血涂片上没有看到独特的形态异常。红细胞PFK活性通常会部分降低(平均30-50%正常),肌肉活检PFK活性明显降低。
>或= 12个月大:5.8-10.9 U/G HB
Reference values have not been established for patients who are <12 months of age.
Clinically significant disorders due to phosphofructokinase (PFK) deficiency are associated with red blood cell activity levels less than 50% of mean normal. Unaffected heterozygotes have been reported with levels of 63% of normal. Therefore genetic correlation will often be important in ambiguous cases.
Recent transfusion may mask the patient's intrinsic erythrocyte (RBC) enzyme activity and cause unreliable results.
Some enzyme deficiency disorders can be masked by reticulocytosis and comparison of activities of other RBC enzyme activities in this panel can be useful.
在正常新生儿中,某些酶缺陷障碍可能会略微降低,或者在新生儿期间被相反掩盖。如果存在肌病的特征,则在1岁之后重复测试很有用。
1. Sherman JB, Raben N, Nicastri C, et al: Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis VII--and their population frequency. Am J Hum Genet. 1994 Aug;55(2):305-313
2. Tarui S,Okuno G,Ikura Y,Tanaka T,Suda M,Nishikawa M:骨骼肌中的磷酸果糖激酶缺乏症。一种新型的糖原病。Biochem Biophys Res Commun。1965年5月3日; 19:517-23。doi:10.1016/0006-291X(65)90156-7
3. Musumeci O,Bruno C,Mongini T等人:肌肉磷酸果糖酶缺乏症(GSD型VII)中的临床特征和新分子发现。神经肌肉疾病。2012年4月; 22(4):325-330
4. Nakajima H,Raben N,Hamaguchi T,Yamasaki T:磷酸果糖酶缺乏症;过去,现在和未来。Curr mol Med。2002年3月; 2(2):197-212。doi:10.2174/1566524024605734
5. Auranen M, Palmio J, Ylikallio E, et al: PFKM gene defect and glycogen storage disease GSDVII with misleading enzyme histochemistry. Neurol Genet. 2015 Jun 4;1(1). doi: 10.1212/NXG.0000000000000007
6. Raben N,Sherman JB:肌肉磷酸果糖激酶基因的突变。哼声。1995; 6(1):1-6。doi:10.1002/humu.1380060102
7. Koralkova P,Van Solinge WW,Van Wijk R:与溶血性贫血病理生理学,临床方面和实验室诊断相关的罕见遗传红细胞酶病。Int J Lab hematol。2014;36:388-397。doi:10.1111/ijlh.12223
磷酸果糖激酶(PFK) catalyzes the phosphorylation of fructose-6-phosphate (F6P) by adenosine triphosphate (ATP) to fructose-1,6-diphosphate (F1,6-diP). F1,6-diP is then converted to dihydroxyacetone phosphate (DHAP) through subsequent aldolase and triosephosphate isomerase (TPI) catalyzed reactions. The rate of formation of DHAP is measured by linking its reduction to alpha-glycerophosphate by alpha-glycerophosphate dehydrogenase which results in the oxidation of1,4-dihydronicotinamide adenine dinucleotideNADH to NAD(+). The decrease in absorbance at 340 nm is measured spectrophotometrically as the NADH is oxidized on an automated chemistry analyzer.(Beutler E: Red cell metabolism. A Manual of Biochemical Methods. 3rd ed. Grune and Stratton; 1984: 68-71;Van Solinge WW,Van Wijk:红细胞的酶。In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:chap 30)
周二周四
该测试是开发的,其性能特征由Mayo诊所以与CLIA要求一致的方式确定。该测试尚未得到美国食品药品监督管理局的清除或批准。
82657
测试ID | Test Order Name | 订单loinc值 |
---|---|---|
PFK1 | 磷脂运动酶,b | 72664-6 |
结果ID | 测试结果名称 | 结果lainc值
仅适用于最初由表演实验室报告的度量单位表达的结果。这些值不适用于转换为其他度量单位的结果。
|
---|---|---|
pfkcl | 磷脂运动酶,b | 72664-6 |